First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience

INTRODUCTION: Clinical trial data has shown pazopanib to be non-inferior in overall survival (OS) compared to sunitinib as first-line treatment for metastatic renal cell carcinoma (mRCC). The purpose of this study was to evaluate outcomes and compare dose-modifying toxicities of mRCC patients treate...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Can Urol Assoc J
Main Authors: Lalani, Aly-Khan A., Li, Haocheng, Heng, Daniel Y.C., Wood, Lori, Kalirai, Austin, Bjarnason, Georg A., Sim, Hao-Wen, Kollmannsberger, Christian K., Kapoor, Anil, Hotte, Sebastien J., Vanhuyse, Marie, Czaykowski, Piotr, Reaume, M. Neil, Soulieres, Denis, Venner, Peter, North, Scott, Basappa, Naveen S.
Formato: Artigo
Idioma:Inglês
Publicado em: Canadian Medical Association 2017
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5434501/
https://ncbi.nlm.nih.gov/pubmed/28515811
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.4398
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados